The global PCSK9 inhibitors market is projected to expand at a rate of 21.5% year over year and reach US$ 2,733.7 million by 2024. The PCSK9 inhibitor market is expected to grow at a compound annual growth rate (CAGR) of 18.7% throughout the forecast period, ending in 2034 with total sales of US$ 15,140.3 million.
The PCSK9 inhibitor market is expected to be dominated by the evolocumab segment, which is expected to hold a 71.3% value share in 2024. However, sales of inclisiran are likely to expand at a staggering CAGR of 31.3% during the assessment period.
Discover Industry Secrets Through Your Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-16339
Key Takeaways:
- The global PCSK9 inhibitor market is projected to reach US$15.14 billion by 2034, reflecting a remarkable CAGR of 18.7%.
- This surge is driven by a significant year-over-year growth of 21.5% in 2024, highlighting the rapid expansion of the market.
- Evolocumab is currently the dominant player, but inclisiran is poised for the fastest growth, with a projected CAGR of 31.3%.
Competitive Landscape:
Clinical trials can serve as a powerful promotional strategy for a company, offering a multifaceted approach to showcasing its commitment to innovation, patient care, and scientific advancement. Securing approval from the U.S. Food and Drug Administration (FDA) is a significant achievement for any pharmaceutical or biopharmaceutical company.
Top manufacturers of PCSK9 inhibitors are heavily investing in research and development to explore novel treatment approaches for high cholesterol. For instance, they are exploring combination therapies with other cholesterol-lowering drugs to broaden the application of PCSK9 inhibitors and improve patient outcomes.
Recent Developments in the PCSK9 Inhibitor Market
- In April 2021, Praluent (alirocumab) injection was approved by the Food and Drug Administration (FDA) for patients with homozygous familial hypercholesterolemia (HoFH).
- In November 2023, LIB Therapeutics completed the global phase 3 LIBerate program of Lerodalcibep, a new third-generation PCSK9 inhibitor in development for cardiovascular diseases.
- In August 2023, Merck initiated the Phase 3 clinical program for oral PCSK9 inhibitor candidate MK-0616. The oral PCSK9 inhibitor (MK-0616) is being evaluated for the treatment of adults with hypercholesterolemia.
Gain Insight Into Our Research Process:
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16339
Key Players in the PCSK9 Inhibitor Market Include:
- Novartis AG
- Regeneron Pharmaceuticals, Inc. (Sanofi)
- Amgen Inc.
- Innovent
- LIB Therapeutics, LLC
- Shanghai Junshi Biosciences Co., Ltd
- Merck & Co., Inc.
- AstraZeneca
Key Market Segments Covered in PCSK9 Inhibitor Industry Research:
By Drug:
- Alirocumab
- Evolocumab
- Inclisiran
- Tafolecimab
By Modality:
- Fully-humanized monoclonal antibodies
- siRNA
By Indication:
- Primary Hyperlipidemia
- Familial Hyper Cholesterolemia
- Prevention of Other Cardiovascular Events
By Sales Channel:
- Hospitals
- Specialty Clinics
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- East Asia
- South Asia & Pacific
- Western Europe
- Eastern Europe
- Middle East & Africa
Secure Your Market Analysis Now: Purchase Now to Access: https://www.futuremarketinsights.com/checkout/16339
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
